1. Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
- Author
-
Egilman, Alexander C., Kesselheim, Aaron S., Sarpatwari, Ameet, and Rome, Benjamin N.
- Subjects
- *
MEDICARE Part D , *GENERIC drugs , *DRUG labeling , *PATENT suits , *EVEROLIMUS - Abstract
This document presents a study on the impact of skinny-label generic competition on Medicare Part D spending from 2015 to 2021. Skinny-label generics are generic drugs that are approved for a subset of the indications of the brand-name drug. The study found that skinny-label generic competition saved Medicare approximately $14.6 billion during this period. The savings were highest for drugs such as Crestor, Lyrica, and Gleevec. The study suggests that skinny-label generics can improve patient access to lower-cost medications and recommends reinforcing the skinny-label pathway to encourage timely generic competition. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF